HER2 is also known as receptor tyrosine-protein kinase erbB-2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2),  metastatic lymph node gene 19 protein, proto-oncogene Neu, p185erbB2. It is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK).  Four members of the EGFR family have been identified: EGFR (ERBB1, HER1), HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4).  They typically contain an extracellular ligand binding domain (ECD), a transmembrane domain (TM), and an intracellular kinase domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity.  EGFR signaling is initiated by ligand binding to the extracellular ligand binding domain. This initiates receptor homo-/hetero-dimerization and autophosphorylation by the intracellular kinase domain, resulting in receptor activation. Following activation, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation.  HER2 has no ligand binding domain of its own and therefore cannot bind growth factors.  However, it does bind tightly to other ligand-bound EGFR family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways.  Amplification or overexpression of HER2 has been reported in multiple cancers, including breast and ovarian tumors.  HER2 is the target of several anti-cancer therapeutics. The purified recombinant monoclonal antibody binds human HER2 with high affinity, blocks HER2 signaling activity and inhibits HER2-overexpressing tumor cell growth.

HER2 is also known as receptor tyrosine-protein kinase erbB-2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2),  metastatic lymph node gene 19 protein, proto-oncogene Neu, p185erbB2. It is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK).  Four members of the EGFR family have been identified: EGFR (ERBB1, HER1), HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4).  They typically contain an extracellular ligand binding domain (ECD), a transmembrane domain (TM), and an intracellular kinase domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity.  EGFR signaling is initiated by ligand binding to the extracellular ligand binding domain. This initiates receptor homo-/hetero-dimerization and autophosphorylation by the intracellular kinase domain, resulting in receptor activation. Following activation, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation.  HER2 has no ligand binding domain of its own and therefore cannot bind growth factors.  However, it does bind tightly to other ligand-bound EGFR family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways.  Amplification or overexpression of HER2 has been reported in multiple cancers, including breast and ovarian tumors.  HER2 is the target of several anti-cancer therapeutics. The purified recombinant monoclonal antibody binds human HER2 with high affinity, blocks HER2 signaling activity and inhibits HER2-overexpressing tumor cell growth.

 

Product Details

 

Gene Symbol: HER2; ERBB2; CD340; NGL; TKR1; MLN19; HER-2/neu

 

NCBI Gene ID: 2064

 

Uniprot Entry: P04626

 

Construct Details: Expressed as the combination of a heavy chain (HC) containing VH from anti-HER2 mAb and CH1-3 region of rabbit IgG  and a light chain (LC) encoding VL from anti-HER2 mAb and CL of rabbit kappa light chain.  Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition (see the gel image above, labeled as DTT "-")

 

Source:  Mamamlian cells stably expressing anti-HER2 rabbit heavy chain and light chain and growing in chemical-defined media with no animal components or antibiotics

 

M.W.: Calculated molecular mass (kDa): 145.8 (49.4 kDa for a single HC, 23.5 kDa for a single LC); Estimated by SDS-PAGE under non-reducing condition(kDa): 150

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as DTT "+")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: The recombinant antibody binds HER2 extracellular domain (SKU#FCL0220, #FCL0088) with high affinity (K_D < 1 nM as measured by ELISA - see the Technical Data) and recognizes cell surface HER2 by flow cytometry, IHC staining and fluorescent microscopy.  This recombinant antibody has the same binding specificity as anti-HER2 hIgG1 (SKU#MAB0203) and anti-HER2 mIgG2a (#MAB0061).

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

 

Technical Data

 

Recombinant HER2 ECD protein (SKU#FCL0220) was immobilized at 10 ng/well on a 96-well ELISA plate and incubated with serially diluted anti-HER2 human IgG1 monoclonal antibody (SKU#MAB0203). Anti-EGFR (SKU#MAB0118) human IgG1 monoclonal antibody was used as a control to demonstrate the specificity of HER2 binding under the experimental conditions.  The bound antibodies were detected by goat anti-human IgG HRP-conjugated secondary antibody.  The ELISA binding curve was fit and K_D was calculated for anti-HER2 : HER2 binding (affinity/avidity) to be 299 ± 13 pM. 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1.  Science 230: 1132–9, 1985
2.  Nature 319:230-234, 1986
3.  Science 229:974-976, 1985
4.  Cancer Cell 5:317-328, 2004

 

 

Documentation

 

 

Product datasheet (pdf) can be downloaded here: MAB0334-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.